<DOC>
	<DOCNO>NCT02417870</DOCNO>
	<brief_summary>To investigate safety tolerability treatment low dose rIL-2 renal transplant recipient . To assess immunologic impact low dose rIL-2 renal transplant recipient . To assess efficacy low dose rIL-2 renal transplant recipient .</brief_summary>
	<brief_title>Ultra-low Dose Subcutaneous IL-2 Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Kidney transplant recipient &gt; 18 year &lt; 75 year age &gt; 6 month post Tx stable dose immunosuppression Transplant biopsy show interstitial fibrosis tubular atrophy grade II great , evidence lymphocytic infiltration ( biopsy NOT study procedure , would perform part patient 's SOC ) Ability give inform consent Biopsy proven acute cellular rejection ; great grade 1A Baseline creatinine &gt; 3.5mg/dL Patients active infection , include Hepatitis B C , HIV Current prior invasive malignancy Patients pregnant breastfeeding Patients unable give consent Prior intolerance of/allergy IL2 Inability comply treatment History thrombotic angiopathy include hemolytic uremic syndrome thrombotic thrombocytopenic purpura Symptomatic congestive cardiac failure uncontrolled cardiac angina Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start study drug . WOCBP male subject reproductive potential must agree use highly effective method birth control [ define protocol &amp; ICF ] study treatment , 6 month completion treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
</DOC>